Ads
related to: fda, pharmaceuticals
Search results
MDMA-Maker Failed Its FDA Hearing — And Its PTSD Patients
Bloomberg· 17 hours agoLykos Therapeutics showed up to a regulatory hearing woefully unprepared. Lisa Jarvis is a Bloomberg...
Goldman starts Jazz at buy, cites diversified portfolio (NASDAQ:JAZZ)
Seeking Alpha· 18 hours agoGoldman Sachs initiated coverage of Jazz Pharmaceuticals (JAZZ) with a buy rating, citing its...
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 18 hours agoWill the recent negative trend continue leading up to its next earnings release, or is Rocket ...
Robert Kennedy Jr. Is Sorry the FDA Didn't Approve Psychedelic Drug MDMA (Ecstasy or Molly) for PTSD...
Showbiz411· 9 hours agoWhat is our potential next president worried about? Robert Kennedy Jr — just kidding– never to be...
Be Bio’s haemophilia B treatment gains FDA orphan drug status
Pharmaceutical Technology via Yahoo Finance· 23 hours agoThe orphan drug designation reinforces the potential of this therapy and underscores the need for...
FDA Declines Approval Of MDMA As Treatment For PTSD
International Business Times· 14 hours agoThe Food and Drug Administration has declined to recommend approval for the use of MDMA, more popularly known as molly or ecstasy, to treat...
Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
The Sun Chronicle· 7 days agoVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that ownership of the U.S. New Drug ...Company, which now fully allows Vanda to commercialize PONVORY® in ...
FDA panel rejects first MDMA treatment amid deep concerns about flawed trials
NBC NEWS· 1 day agoIf approved by the FDA, it would be the first new treatment for PTSD in more than two decades. The...
MDMA therapy wait goes on as FDA panel rejects Lykos’ PTSD treatment
Pharmaceutical Technology via Yahoo Finance· 23 hours agoThe two companies will pursue neuroplastogens – agents that induce rapid and long-lasting...
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol...
Benzinga via Yahoo Finance· 22 hours agoWednesday, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) announced that the first patient had been dosed...